Sol-Gel Technologies (SLGL) Other Accumulated Expenses (2017 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Other Accumulated Expenses of $3.3 million for Q2 2025, down 20.23% year-over-year from $4.1 million in Q2 2024, and down 7.86% quarter-over-quarter from $3.6 million in Q4 2024.
Analysis
Sol-Gel Technologies (SLGL) Other Accumulated Expenses (2017 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Other Accumulated Expenses for 8 consecutive years, with $3.3 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Other Accumulated Expenses fell 20.23% year-over-year to $3.3 million; the TTM figure through Jun 2025 stood at $3.3 million (down 20.23% YoY), while the FY2024 annual figure was $3.6 million, down 8.44% from the prior year.
- Other Accumulated Expenses eased to $3.3 million in Q2 2025 per SLGL's latest filing, from $3.6 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $10.1 million in Q4 2021 and bottomed at $1.7 million in Q2 2022.
- Historically, Other Accumulated Expenses has averaged $4.1 million across 5 years, with a median of $3.6 million in 2024.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses tumbled 76.74% — and 2023, when it surged 186.84%.
- Sol-Gel Technologies' Other Accumulated Expenses stood at $10.1 million in 2021, then sank by 76.74% to $2.4 million in 2022, then surged by 66.14% to $3.9 million in 2023, then retreated by 8.44% to $3.6 million in 2024, then fell by 7.86% to $3.3 million in 2025.
- Business Quant data shows SLGL's Other Accumulated Expenses at $3.3 million in Q2 2025, $3.6 million in Q4 2024, and $4.1 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 3.31 Mn |
| Dec 31, 2024 | 3.59 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Dec 31, 2022 | 2.36 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Dec 31, 2021 | 10.15 Mn |
| Jun 30, 2021 | 3.16 Mn |
| Dec 31, 2020 | 4.09 Mn |
| Dec 31, 2018 | 43,000.00 |
| Dec 31, 2017 | 46,000.00 |